A minimally invasive orthobiologic procedure designed for the treatment of osteoarthritis and cartilage degeneration using tissue-specific autologous micrografts.
Talk to a SpecialistA minimally invasive orthobiologic procedure designed for the treatment of osteoarthritis and cartilage degeneration using tissue-specific autologous micrografts.
Mytocel MSK uses mechanical micrografts preserving tissue-specific cells and matrix; PRP is a blood-derived product with growth factors. They are distinct therapies.
Mytocel MSK is an autologous micrograft therapy used to support cartilage regeneration with a standardized, minimally invasive protocol.
Mytocel MSK is indicated for certain degenerative joint conditions; follow local regulatory guidance and product labeling.
Contraindications include active infection at the injection site and other clinical exclusions; consult the product protocol.
Contraindications include active infection at the injection site and other clinical exclusions; consult the product protocol.
Contraindications include active infection at the injection site and other clinical exclusions; consult the product protocol.
Clinical outcomes depend on condition severity; review published evidence and clinical judgement for grade IV OA.
Duration of benefit varies; refer to clinical studies for expected timelines and patient selection factors.
Mytocel MSK uses mechanical micrografts preserving tissue-specific cells and matrix; PRP is a blood-derived product with growth factors. They are distinct therapies.
Mytocel MSK uses mechanical micrografts preserving tissue-specific cells and matrix; PRP is a blood-derived product with growth factors. They are distinct therapies.
